EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.
EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.
2018 Korea CPHI, C30
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.
1.
Avibactam, CAS#1192491-61-4, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than 1KG in stock, pls check:
Name:Avibactam
CAS#: 1192491-61-4
Formula: C7H10N3NaO6S
Exact Mass:
Molecular Weight: 287.22
Elemental Analysis: C, 29.27; H, 3.51; N, 14.63; Na, 8.00; O, 33.42; S, 11.16
Exact Mass:
Molecular Weight: 287.22
Elemental Analysis: C, 29.27; H, 3.51; N, 14.63; Na, 8.00; O, 33.42; S, 11.16
Appearance: white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
2.
Avibactam Intermediates:
1. Avibactam Intermediate:(2S,5R)-Methyl-5-[(benzyloxy)amino]piperidine-2-carboxylate ethanedioate (1:1)
Cas#1416134-48-9
We have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
1. Avibactam Intermediate:(2S,5R)-Methyl-5-[(benzyloxy)amino]piperidine-2-carboxylate ethanedioate (1:1)
Cas#1416134-48-9
We have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
2. Avibactam Intermediate:(2S,5R)-5-[(benzyloxy)amino]piperidine-2-carboxamide
Cas#1416134-49-0
We have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Cas#1416134-49-0
We have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Rereference：
1: Krishnan NP, Nguyen NQ, Papp-Wallace KM, Bonomo RA, van den Akker F. Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study. PLoS One. 2015 Sep 4;10(9):e0136813. doi: 10.1371/journal.pone.0136813. eCollection 2015. PubMed PMID: 26340563.2: Caravaca-Fontán F, Jiménez-Álvaro S, Marcén-Letosa R, Fernández-Rodríguez A, Rodríguez-Navarro CQ. Ceftazidime-avibactam in urinary tract infections due to carbapenemase-producing Klebsiella in kidney transplantation. Nefrologia. 2015 Jul 22. pii: S0211-6995(15)00070-3. doi: 10.1016/j.nefro.2015.01.001. [Epub ahead of print] English, Spanish. PubMed PMID: 26306955.
3: Zasowski EJ, Rybak JM, Rybak MJ. The β-Lactams Strike Back: Ceftazidime-Avibactam. Pharmacotherapy. 2015 Aug;35(8):755-70. doi: 10.1002/phar.1622. PubMed PMID: 26289307; PubMed Central PMCID: PMC4545577.
4: Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, Gregson A. First report of ceftazidime-avibactam resistance in a KPC-3 expressing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2015 Jul 20. pii: AAC.01165-15. [Epub ahead of print] PubMed PMID: 26195508.
5: Shields RK, Clancy CJ, Hao B, Chen L, Press EG, Iovine NM, Kreiswirth BN, Nguyen MH. Effects of Klebsiella pneumoniae Carbapenemase Subtypes, Extended-Spectrum β-Lactamases, and Porin Mutations on the In Vitro Activity of Ceftazidime-Avibactam against Carbapenem-Resistant K. pneumoniae. Antimicrob Agents Chemother. 2015 Sep;59(9):5793-7. doi: 10.1128/AAC.00548-15. Epub 2015 Jul 13. PubMed PMID: 26169413.
6: Sillén H, Mitchell R, Sleigh R, Mainwaring G, Catton K, Houghton R, Glendining K. Determination of avibactam and ceftazidime in human plasma samples by LC-MS. Bioanalysis. 2015 Jul;7(12):1423-34. doi: 10.4155/bio.15.76. PubMed PMID: 26168250.
7: Sader HS, Castanheira M, Farrell DJ, Flamm RK, Jones RN. Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014). Diagn Microbiol Infect Dis. 2015 Jun 17. pii: S0732-8893(15)00211-4. doi: 10.1016/j.diagmicrobio.2015.06.008. [Epub ahead of print] PubMed PMID: 26162518.
8: Nicolau DP. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. Expert Opin Investig Drugs. 2015 Sep;24(9):1261-73. doi: 10.1517/13543784.2015.1062873. Epub 2015 Jul 6. PubMed PMID: 26145447.
9: Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2015 Sep;46(3):266-71. doi: 10.1016/j.ijantimicag.2015.05.003. Epub 2015 Jun 14. Review. PubMed PMID: 26143591.
10: Nicolau DP, Siew L, Armstrong J, Li J, Edeki T, Learoyd M, Das S. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. J Antimicrob Chemother. 2015 Jul 1. pii: dkv170. [Epub ahead of print] PubMed PMID: 26133566.
11: Livermore DM, Warner M, Jamrozy D, Mushtaq S, Nichols WW, Mustafa N, Woodford N. In Vitro Selection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase. Antimicrob Agents Chemother. 2015 Sep;59(9):5324-30. doi: 10.1128/AAC.00678-15. Epub 2015 Jun 22. PubMed PMID: 26100712.
12: Tominaga N, Edeki T, Li J, Learoyd M, Bouw MR, Das S. Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers. J Infect Chemother. 2015 Aug;21(8):551-8. doi: 10.1016/j.jiac.2015.04.006. Epub 2015 Apr 28. PubMed PMID: 26076867.
13: Singh R, Kim A, Tanudra MA, Harris JJ, McLaughlin RE, Patey S, O'Donnell JP, Bradford PA, Eakin AE. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. J Antimicrob Chemother. 2015 Sep;70(9):2618-26. doi: 10.1093/jac/dkv132. Epub 2015 May 29. PubMed PMID: 26024868.
14: Jones RN, Holliday NM, Krause KM. Validation of Sensititre Dry-Form Broth Microdilution Panels for Susceptibility Testing of Ceftazidime-Avibactam, a Broad-Spectrum-β-Lactamase Inhibitor Combination. Antimicrob Agents Chemother. 2015 Aug;59(8):5036-9. doi: 10.1128/AAC.00021-15. Epub 2015 May 26. PubMed PMID: 26014937; PubMed Central PMCID: PMC4505265.
15: Ceftazidime/Avibactam (Avycaz) -- a new intraveneous antibiotic. Med Lett Drugs Ther. 2015 May 25;57(1469):79-80. PubMed PMID: 25989198.
16: Rashid MU, Rosenborg S, Panagiotidis G, Söderberg-Löfdal K, Weintraub A, Nord CE. Ecological Effect of Ceftaroline-Avibactam on the Normal Human Intestinal Microbiota. Antimicrob Agents Chemother. 2015 Aug;59(8):4504-9. doi: 10.1128/AAC.00530-15. Epub 2015 May 18. PubMed PMID: 25987638; PubMed Central PMCID: PMC4505277.
17: Rashid MU, Rosenborg S, Panagiotidis G, Löfdal KS, Weintraub A, Nord CE. Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota. Int J Antimicrob Agents. 2015 Jul;46(1):60-5. doi: 10.1016/j.ijantimicag.2015.02.027. Epub 2015 Apr 20. PubMed PMID: 25979639.
18: Biedenbach DJ, Kazmierczak K, Bouchillon SK, Sahm DF, Bradford PA. In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013. Antimicrob Agents Chemother. 2015 Jul;59(7):4239-48. doi: 10.1128/AAC.00206-15. Epub 2015 May 11. PubMed PMID: 25963984; PubMed Central PMCID: PMC4468705.
19: Winkler ML, Papp-Wallace KM, Bonomo RA. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop. J Antimicrob Chemother. 2015 Aug;70(8):2279-86. doi: 10.1093/jac/dkv094. Epub 2015 May 8. PubMed PMID: 25957381; PubMed Central PMCID: PMC4500773.
20: Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. Int J Antimicrob Agents. 2015 Jul;46(1):53-9. doi: 10.1016/j.ijantimicag.2015.02.022. Epub 2015 Apr 14. PubMed PMID: 25956844.
